Cite
HARVARD Citation
Hagiwara, A. et al. (2022). Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors. Neuro-oncology. 24 (6), pp. 1020-1028. [Online].